SAN DIEGO–(BUSINESS WIRE)–Capstan Therapeutics, Inc. (“Capstan”), a biotechnology company dedicated to advancing in vivo reprogramming of cells through RNA delivery using targeted lipid nanoparticles (tLNP), today announced that the Company will participate in the following investor conferences:
Goldman Sachs Cell Therapy Day 2024
Date: Tuesday, October 1, 2024
Location: New York, NY
Chief Medical Officer, Ramin Farzaneh-Far, M.D., will participate in a panel discussion focused on innovations in cell therapies.
Leerink Partners Biopharma Private Company Connect
Date: Tuesday, October 22 and Wednesday, October 23, 2024
Location: Virtual
Capstan management will participate in virtual 1×1 investor meetings.
About Capstan Therapeutics, Inc. (www.capstantx.com)
Capstan is a biotechnology company with a mission to multiply the therapeutic possibilities for patients by developing targeted in vivo RNA technologies. Our proprietary CellSeeker™ tLNP platform technology is composed of LNPs conjugated with a recombinant protein binder, such as a monoclonal antibody. tLNPs are designed to deliver payloads, including mRNA or gene editing tools, capable of reprogramming specific cell types in vivo. Capstan’s CellSeeker™ technology has the potential to generate transformative therapies with possible applications across a broad range of disease areas, including autoimmune disorders, oncology, fibrosis, and monogenic blood disorders. For more information, please visit www.capstantx.com and follow us on LinkedIn and X (Twitter).
Contacts
Investors:
Miguel Arcinas
Senior Vice President of Corporate Development
Capstan Therapeutics
marcinas@capstantx.com
Media:
Rhiannon Jeselonis
Ten Bridge Communications
rhiannon@tenbridgecommunications.com
